The p53 tumor suppressor gene lies at the crossroads of multiple cellular response pathways that control a cell's fate in response to endogenous or exogenous stresses. Positive and negative regulatory loops both upstream and downstream of p53 cooperate to ®nely tune its functions as a transcription factor, a DNA damage sensor, and possibly, a protein-assembly scaold. Through this plethora of activities, p53 is a major determinant of cell survival and a safeguard against genetic instability. Functional inactivation of p53 pathways through genetic and epigenetic events aecting the p53 gene itself and/or its interacting partners occur with a high frequency in lung cancer. The p53 mutational spectrum provides molecular evidence of the etiology of lung cancer and supports abundant epidemiological data indicating the role of tobacco smoke in the causation of this disease.
Introduction
Since the discovery of the tumor suppressor p53 nearly two decades ago, an overwhelming volume of literature has accumulated supporting its role as a central regulatory node in the protein network that mediates cellular responses to endogenous and exogenous stresses (Oren, 1999; Prives and Hall, 1999; Vogelstein et al., 2000) . Disabling this pathway through mutation or silencing of its components, leads to cell transformation, and along with the functional loss of the pRb-p16 pathway (reviewed by FJ Kaye in this issue of Oncogene), is thought to contribute to tumorigenesis. The p53 gene itself is mutated in over half of all human cancers (Hollstein et al., 1991; Nigro et al., 1989) , including lung cancer (Takahashi et al., 1989) . Here, we will review the molecular components of the p53 network and their alterations in lung cancers. We will also examine the p53 mutational spectrum, frequency and timing, as a hypothesis-generating tool to study the etiology of lung cancer (Hussain and Harris, 1998) .
The p53 network
The p53 protein consists of 393 amino acids, which can be conceptually divided into ®ve major domains characterized by speci®c structures and functions ( Figure 1) . The acidic N-terminal domain (aa 1 ± 50) is required for transcriptional activation and is the binding site of the negative regulator HDM2, which mediates p53 ubiquitin-dependent proteolysis (Haupt et al., 1997; Kubbutat et al., 1997) . The proline-rich region (aa 61 ± 94) contains ®ve repeats of the sequence, PXXP (P designating proline and X designating any amino acid). This motif is capable of mediating interactions with signal transduction molecules that contain a SH3-binding domain, and seems to be required for ecient p53-mediated growth suppression and apoptosis (Venot et al., 1998; Walker and Levine, 1996) . The central core (aa 97 ± 300) contains a sequence-speci®c DNA-binding domain. Most p53 mutations in human cancers are missense and map to this portion of the protein, leading to its loss of function as a transcription factor (Hollstein et al., 1994) . Gene transactivation by p53 is thus thought to play a major role in its tumor suppressing activity (Vogelstein et al., 2000) . The p53 molecule binds to its cognate sequence as a homotetramer, hence the tetramerization domain (aa 324 ± 352) is essential for sequence-speci®c binding and transactivation. The basic C-terminal domain (aa 363 ± 393) may perform a regulatory function over the core domain (Hupp et al., 1992) , recognizes some DNA lesions (Jayaraman and Prives, 1995; Lee et al., 1995) , and interacts with helicases involved in DNA repair, DNA recombination, and apoptosis .
Upstream signals
There is a low level of latent and posttranscriptionally modi®ed p53 in normal cells, but it is activated through further posttranscriptional modi®cations in response to a variety of cellular stresses, leading to nuclear accumulation (Appella and Anderson, 2001; Prives and Hall, 1999) . These stresses include DNA damage (Kastan et al., 1991) , oncogene activation (Kamijo et al., 1998) , hypoxia (Graeber et al., 1994) , hyperploidy (Cross et al., 1995; Di Leonardo et al., 1997) , ribonucleotide depletion (Linke et al., 1996) , and loss of cell adhesion (Nigro et al., 1997) .
At least two pathways leading to p53 stabilization have been described (Figure 2 ). One pathway involves responses to genotoxic stresses, such as DNA damage caused by ionizing or ultraviolet radiation. Stressinduced kinases, including ATM, ATR, CHK2, and HIPK2 phosphorylate a number of serine and threonine residues in the N-terminal transactivation domain of p53 (Appella and Anderson, 2001; D'Orazi et al., 2002; Hofmann et al., 2002) . Phosphorylation of the p53 N-terminus inhibits binding of its negative regulator, HDM2, and enhances transcriptional regulation of p53 target genes. The other pathway involves p14
ARF upregulation in response to aberrant mitogenic signals, such as Myc overexpression or E2F-1 activation arising from E1A or activated Ras expression (Bates et al., 1998; Palmero et al., 1998; Sherr, 2001) . p14 ARF can stabilize p53 by binding to HDM2 and sequestering it in nucleoli (Weber et al., 2000a) . This pathway serves as a link between p53 growth-suppressing functions and E2F-1 growthpromoting functions, so that aberrant mitogenic signals will trigger a compensatory response to limit proliferation (Sherr, 2001) . It is unclear whether the DNA damage and p14 ARF -mediated pathways of p53 activation are completely independent, because activated oncogenes also can induce DNA damage through the generation of reactive oxygen species (Wahl and Carr, 2001) . p53 stabilization in response to other stresses is not well characterized. In addition to the N-terminal serine and threonine residues, some other sites on p53 undergo posttranslational modi®ca-tions, including phosphorylation, acetylation, and sumoylation. For example, lysine 320 is acetylated by PCAF, and lysines 373 and 382 are acetylated by CBP/p300 (Appella and Anderson, 2001 ). Although there is some evidence that such modi®cations can lead to the stabilization and/or enhancement of transcriptional regulation by p53, the physiological roles of these modi®cations remains controversial (Prives and Manley, 2001) . 
Downstream effects
p53 exerts its pleiotropic eects by both transcriptiondependent and transcription-independent mechanisms (Figure 2 ). p53 activation leads to homotetramerization, enabling its transcriptional activation function. p53 can induce transient cell cycle arrest in G1 or G2 by transactivating target genes such as p21 CIP1/WAF1 and 14-3-3s (El-Deiry et al., 1993 , Harper et al., 1993 Hermeking et al., 1997) . Arrest at these cell cycle checkpoints during stress may prevent progression under inappropriate conditions, thereby inhibiting the accumulation of genetic errors. p53 can also initiate permanent arrest, or senescence, through the transactivation of p21 CIP1/WAF1 (Di Leonardo et al., 1994; Itahana et al., 2001) . This senescence-associated activity of p53 can be modulated by PML and p33
ING1 (Pearson et al., 2000; Garkavtsev and Riabowol, 1997) , and recent data on genetically engineered mice suggests that chronically active p53 leads to premature ageing (Tyner et al., 2002) . Alternatively, p53 can initiate apoptosis through the transactivation of genes such as Bax (Miyashita and Reed, 1995) , Killer/DR5 (Wu et al., 1997) , PIG3 , and APAF-1 (Moroni et al., 2001; Robles et al., 2001) . In addition, p53 can initiate apoptosis in a transcription-independent manner, possibly through physical interactions with members of the DexHcontaining DNA helicase superfamily, including BLM, XPB, XPD, and WRN (Spillare et al., 1999; Wang et al., 1995 Wang et al., , 1996 Wang et al., , 2001 ). Initiation of either apoptosis or senescence inhibits tumorigenesis through the elimination of potentially mutated cells from the reproductively viable population. p53-dependent repression of transcription has also been described, although much less is known about this activity.
p53 plays a role in several DNA repair pathways as well ( Figure 2 ). Wild-type p53 enhances global genomic nucleotide excision repair (Wang et al., 1995; Ford and Hanawalt, 1995) , perhaps through the transactivation of p48/DDB2 (Hwang et al., 1999) and/or GADD45 (Smith et al., 2000a) . p53 transcription-independent functions in base excision repair (BER) and homologous recombination repair (HRR) indicate a more direct role in these pathways. p53 appears to enhance BER, perhaps through an association with the AP endonuclease (APE) and/or DNA polymerase b (Polb) (Oer et al., 1999; Zhou et al., 2001) . In contrast, most reports indicate that p53 negatively regulates HRR (Dudenhoer et al., 1999; Saintigny et al., 1999) . In support of these observations, p53 can bind to and inhibit the central HRR factor Rad51 (Buchhop et al., 1997; Sturzbecher et al., 1996) , and recombination rates tend to be signi®cantly elevated in p53-de®cient cells (Bertrand et al., 1997; Gebow et al., 2000; Honma et al., 1997; Mekeel et al., 1997; Wiesmuller et al., 1996) . p53 also associates with BRCA1, which has been implicated in HRR (Ouchi et al., 1998) . It remains unclear whether p53 post translational modi®cations are necessary for its transcription-independent functions, or how activation aects these functions, including its ability to bind to associated proteins.
p53 homologues
An unexpected twist to this already complicated scheme, was the discovery of two p53 homologues, p73 and p63, which also share two of p53's characteristic functions: gene transactivation and apoptotic induction (Irwin and Kaelin, 2001 ). In particular, p73 became the focus of much attention as a potential safeguard against p53 inactivation when it was shown to be regulated by the tyrosine kinase c-Abl after exposing cells to ionizing radiation or cisplatin, which lead to the transactivation of known p53 transcriptional targets and apoptosis (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . More recently, it became apparent that p73 is a mediator of oncogenic signalling pathways as well. E2F-1 can upregulate the transcription of p73 directly, leading to p53-independent apoptosis . However, p53 mutants have been found to bind p73 and inhibit its transcriptional and apoptotic functions (Di Como et al., 1999) , consistent with a proposed gain-of-function exhibited by certain p53 mutants (Sigal and Rotter, 2000) . Such interactions may have an impact in the development of tumor chemoresistance (Strano et al., 2000) . Moreover, a recent report showed a requirement for p63 and p73 in the upregulation of p53 transcriptional targets that medicate apoptosis (Flores et al., 2002) , thus, implicating p63 and p73 directly in tumor chemosensitivity.
Codon 72 polymorphic variant and lung cancer risk
Two common polymorphic variants have been described at codon 72 of wild-type p53. The polymorphism derives from a single-nucleotide substitution that results in either proline (p53pro) or arginine (p53arg) at codon 72. This nonconservative amino acid change involves one of the ®ve PXXP SH3-binding motifs found in the p53 proline-rich domain (Figure 1 ) and aects certain p53 biochemical and functional properties. p53pro is a strong transcriptional activator, but a poorer inducer of apoptosis than p53arg . In addition, p53arg is more susceptible to degradation by the human papillomavirus E6 protein (Storey et al., 1998) . Furthermore, for p53 mutants that bind to p73, those that carry the arginine polymorphism tend to block the p73 apoptotic function more eectively . Although these phenotypes do not suggest a clear role for the codon 72 polymorphism in the inherited susceptibility to lung cancer, several epidemiological studies have reported an association between the presence of a pro/ pro genotype and the risk for adenocarcinoma development (Fan et al., 2000; Liu et al., 2001; Weston et al., 1992) . Interestingly, an arg/arg genotype confers increased risk of squamous cell carcinoma in individuals de®cient in a metabolizing enzyme involved in the detoxi®cation of tobacco carcinogens (Liu et al., 2001) . This is consistent with the preferential mutation of the p53arg allele found in squamous tumors . From these studies, it can be argued that the presence of a pro/pro genotype aects overall lung cancer development because of its poorer apoptotic properties. However, the absence of detoxifying enzymes may lead to a longer exposure to active carcinogens and the selection for mutant p53 that carries an arginine polymorphism, which would more eectively block the p73 safeguard apoptotic function.
Dysregulation of the p53 network in lung cancers
Mutation of the p53 gene is the main event that leads to the inactivation of the p53 stress-response pathway in lung cancers. Such mutations would provide precancerous cells with a selective advantage for unregulated growth and the acquisition of genetic instability. The distribution of mutations along p53 in all cancers is not random, but rather characterized by mutational hotspots mostly concentrated within the relatively small sequence-speci®c DNA-binding domain ( Figure 5 ). Approximately 75% of these mutations are missense. In contrast, most mutations in other tumor suppressor genes are`loss of function', nonsense, or frameshift mutations (Figure 3) . One likely explanation for this dierence is that single amino acid changes often result in a`loss of function' when they occur on a transcription factor with a discrete DNA-binding domain, like p53. Crystallographic studies of the contact of the p53 DNA-binding domain with its cognate sequence support this explanation. The residues involved directly in contact with DNA or indirectly in the correct folding of p53 coincide with Figure 3 Comparison of the class of mutations found in the tumor suppressor genes p53, APC, ATM, and BRCA1. Missense mutations are largely over-represented in p53, whereas most mutations in the others are frameshift, nonsense, or splice site mutations that commonly lead to truncated proteins. Color codes are indicated p53 mutational hotspots in cancer (Cho et al., 1994) . Such substitutions completely abrogate DNA binding and gene transactivation. In addition, missense amino acid substitutions outside of the region that contacts DNA can lead to alterations in protein conformation, and they may even result in a`gain of oncogenic function' (Sigal and Rotter, 2000) . These features, together with the high frequency of p53 mutations in human cancers, distinguish the p53 gene from other tumor suppressors. A sizable database of p53 mutations has been generated (http://www.iarc.fr/p53), which currently contains more than 15 000 mutations, of which 1789 are from lung cancers.
p53 mutations are present in more than 90% of small cell lung cancers (SCLCs) and more than 50% of nonsmall cell lung cancers (NSCLCs) (Wistuba et al., 2001 ; http://www.iarc.fr/p53). This dierence in mutational frequency may highlight one aspect of what are thought to be distinct pathways of tumorigenesis. Loss of p53 function is an early event in lung tumorigenesis. p53 mutations and protein stabilization have been observed in preneoplastic lesions, such as bronchial epithelial dysplasia Sozzi et al., 1992; Sundaresan et al., 1992; Vahakangas et al., 1992) . Recently, p53 mutations were found in nontumorous peripheral lung tissue from lung cancer patients, supporting their role in the etiology of lung cancer (Hussain et al., 2001) .
Genetic and epigenetic events involving other members of the p53 network have been described in lung cancers as well (Figure 4 ). Ampli®cation of HDM2 or loss of p14 ARF function are known to inactivate p53 pathways in human tumors (Sherr, 2000) . A small percentage of NSCLC exhibit HDM2 ampli®cation and overexpression in the absence of p53 mutations (Marchetti et al., 1995) . Later studies have failed to ®nd any HDM2 mutations in NSCLC (Mariatos et al., 2000) . Because p14 ARF presumably acts upstream of p53 to enhance its activity, Chin et al. (1998) have suggested that loss of either p14 ARF or p53 should be functionally equivalent. The loss of both activities would, therefore, be redundant and unlikely to be selected in human tumors. However, new evidence indicates that mutation of p53 and loss of p14 ARF by homozygous deletion coexist in a subset of NSCLCs (Nicholson et al., 2001; Sanchez-Cespedes et al., 1999) and high-grade neuroendocrine tumors (Gazzeri et al., 1998) . This is consistent with p53-independent functions of p14 ARF (Weber et al., 2000b) , including the observation that p14 ARF can bind to and inhibit E2F-1 transcriptional activity (Eymin et al., 2001a) . Expression of E2F-1 is upregulated in some SCLCs (Eymin et al., 2001b) , which may explain the initially surprising observation that some lung cancers overexpress p73 (Mai et al., 1998) . It is possible that high p73 expression is tolerated in lung cancers because of its inactivating association with mutant p53. In general, however, de®ning the roles for p73 and p63 in tumor development has been elusive. Despite extensive studies, only a few p73 mutations and no p63 mutations have been found in lung cancer cell lines Yoshikawa et al., 1999) , although some p63 isoforms might be oncogenic in the lung (Hibi et al., 2000) . There seems to be a subgroup of NSCLCs, however, in which LOH of p73 occurs concomitantly with abnormalities in either p14 ARF or p53, or both (Nicholson et al., 2001 ). In such cases, abrogation of a back-up p73 apoptotic pathway through haploinsuciency may impart a selective growth advantage to cells with E2F-1 dysregulation, thereby promoting tumor development (Figure 4 ).
p53 mutational spectra in lung cancers
The analyses of the frequency, type, and pattern of p53 mutations in lung cancers have provided strong support to epidemiological data regarding the prevalence of cigarette smoking as the major cause of this disease (Table 1) (Hainaut and Pfeifer, 2001; Hussain and Harris, 1998 ) (reviewed by PG Shields in this issue of Oncogene). Among many other components, cigarette smoke contains polycyclic aromatic hydrocarbons (PAHs) and N-nitrosamines, which are known carcinogens (Hecht, 1999 ; International Agency on the Research of Cancer, 1986). The concentration of PAHs, including benzo[a]pyrene (B[a]P), is higher in the lungs of smokers and is directly dependent on smoking intensity (Goldman et al., 2001) . PAH adducts on DNA have been found in tissues exposed to tobacco smoke (Weston et al., 1993) , and their levels correlate with smoking intensity and age at smoking initiation (Wiencke et al., 1999) .
The p53 mutational spectrum of all cancers is dominated by C to T transitions, the majority of which occur at six mutational hotspots: codons 175, Figure 4 The balance of E2F-1-mediated signals is altered in lung cancers. Aberrant mitogenic signals are tolerated when apoptotic signals mediated by p14 ARF , p53, and p73 have been abrogated through genetic or epigenetic mechanisms. Proliferation becomes unregulated and thus, favors tumor development 245, 248, 249, 273, and 282 (Figure 5a ). With the exception of codon 249, all other mutational hotspots contain methylated CpG sequences. Deamination of endogenous 5-methycytosine bases to thymine is a likely mechanism for transition mutations. There is clearly an increased frequency of G to T transversions in lung cancers of smokers (33%) compared with lung cancers of nonsmokers (15%) and with all cancers (15%) (Figure 5 ) (For a detailed assessment see Hainaut and Pfeifer, 2001) . Mutational hotspots for G to T transversions in lung cancers from smokers are found in methylated CpG sequences at codons 157, 158, 245, 248, and 273 (Figure 5b ). Methylated CpG sequences are the preferential targets for adduct formation and mutagenesis by the ultimate carcinogen metabolite of B[a]P, B[a]P diol epoxide (BPDE), in bronchial epithelial cells (Smith et al., 2000b; Yoon et al., 2001) . Most G to T transversions at p53 mutational hotspots have been attributed to guanines in the nontranscribed strand (NTS) (Hainaut and Pfeifer, 2001) . The slow repair of bulky adducts in the NTS of p53 may explain this observation, indicating that the interplay of carcinogen exposure and DNA repair status may aect an individual's susceptibility to lung cancer. This is supported by a recent report indicating that inactivation of the DNA repair protein O 6 -methylguanine-DNA methyltransferase through promoter hypermethylation results in an increase in G to A transitions at CpG sites in lung cancers (Wolf et al., 2001) . Thus, less ecient repair of mutagenic adducts in the transcribed strand can modify the p53 mutational spectrum. Codon 179, which is also a hotspot for p53 mutations in lung cancer, does not contain a guanine on the NTS, and the most frequent mutation at this codon is a G to A transition at the second position (Hernandez-Boussard and Hainaut, 1998) . Codons 175 and 282 are major p53 mutational hotspots in all cancers, but they are under-represented in lung cancers ( Figure 5 ). Transition mutations without strand bias are the most common type of mutation involving these codons in all cancers as well.
More de®nitive validation of the role of BPDE as a carcinogen that shapes the p53 mutational spectrum in lung cancers comes from the evaluation of the p53 mutational load in nontumorous lung tissue (Hussain et al., 2001) . A high frequency of G to T transversions at codons 157 and 249 of p53 was found in nontumorous peripheral lung tissue in lung cancer cases among smokers (Hussain et al., 2001) . Interestingly, codon 157 mutations are infrequent in other cancers, including lung cancers from never-smokers (Hainaut and Pfeifer, 2001) . A G to T transversion at the second position of codon 249 (AGG to ATG, arginine to methionine) is the most prevalent missense mutation at this codon in lung cancer. It also is a type of mutation that rarely occurs in cancers at other sites (Hernandez-Boussard and Hainaut, 1998) .
Proof of principle that the p53 mutational spectrum in lung cancer indeed re¯ects a speci®c genotoxic exposure to PAHs comes from a recent analysis of p53 mutations in lung tumors from non-smokers exposed to smoky coal emissions (DeMarini et al., 2001) . Smoky coal emissions are rich in PAHs and have been linked epidemiologically to lung cancer independently of cigarette smoke. The predominance of G to T transversions (75%) attributable to guanines in the NTS in these tumors is consistent with PAH-adduct formation at CpG sites (Figure 5d ). In addition, the p53 mutational hotspots coincide with PAH-induced adducts, cigarette smoke-associated mutations, or both (DeMarini et al., 2001) . Interestingly, one of the mutational hotspots in tumors associated with exposure to smoky coal emissions is an arginine to methionine substitution in codon 249 of p53 (DeMarini et al., 2001 ). This mutation is frequent in lung cancers from smokers as well as non smokers ( Figure 5 ). It is possible that a mutagenic PAH present in smoky coal emissions as well as in passive smoke and/or other environmental sources could target codon 249 for mutation. Alternatively, other mechanisms, like oxidative stress leading to lipid peroxidation, may cause this mutation (Hussain et al., 2001) .
The role of tobacco smoke in the causation of genetic damage in the lung rather than in the selection of pre-existing p53 mutants (Rodin and Rodin, 2000) is further illustrated in a recent study of lung cancers from non-smoking and ex-smoking women (Vahakangas et al., 2001) . In this population-based case-control study, lung cancers from ex-smokers showed a higher frequency of p53 mutations, with a higher incidence of G to A transversions. The similarity of the p53 mutational spectra in lung cancers from ex-smokers and current smokers supports the presence of common genotoxic damage that, based on the biochemical activity of PAHs (Table 1) , can be attributed to cigarette exposure.
Concluding remarks
The study of the frequency, pattern, and spectra of p53 mutations in lung cancer is consistent with the hypothesis that speci®c environmental insults can be traced as cancer-causing agents through their`signature mutations' (Hollstein et al., 1991) . This innovative idea opened a new area of research in which epidemiology and molecular biology intersect to better de®ne gene-environment interactions involved in cancer development. It has also provided compelling evidence for the role of carcinogenic components of tobacco smoke in the etiology of lung cancer, although the precise mechanisms need to be clari®ed. Future studies may contribute to our understanding of the role of genetic susceptibility in lung carcinogenesis. However, the current lung cancer epidemic is undoubtedly linked to the addictive nature of tobacco use, and promoting smoking prevention and smoking cessation programs would provide the most bene®t to public health. (Takahashi et al., 1989; Takeshima et al., 1993) . Specificity A G to T transversion at codon 157 of p53 (GTC to TTC) is frequent in lung cancers from smokers, but not in other types of cancer, including lung cancers from never-smokers (Hainaut and Pfeifer, 2001 ). The p53 codon 157 (GTC to TTC) mutation can be found in nontumorous peripheral lung tissue from lung cancer patients (Hussain et al., 2001 ) Temporality p53 mutations can be found in bronchial dysplasia (Sozzi et al., 1992; Sundaresan et al., 1992; Vahakangas et al., 1992) 
Biological plausbility
Tobacco smoke contains B[a]P and other known carcinogens (Hecht, 1999 ; International Agency on the Research of Cancer, 1986). Cigarette smoking is associated with a dose-dependent increase in B[a]P concentration and DNA adducts in lung and other tissues of smokers (Goldman et al., 2001; Weston et al., 1993) . Metabolic activation of B[a]P to its diol epoxide form (BPDE) leads to the formation of BPDE-DNA adducts in human bronchial cells in vitro (Harris et al., 1974; Jeffrey et al., 1977) . BPDE binds to guanine residues in codons 157, 248, and 273, which are p53 mutational hotspots in lung tumors (Denissenko et al., 1996) . Exposure of bronchial epithelial cells to BPDE results in codon 157 (GTC to TTC) and codon 248 (CGG to CTG) mutations (Hussain et al., 2001 ). Cigarette smoking condensates or B[a]P neoplastically transform human bronchial epithelial cells in the laboratory (Iizasa et al., 1993; Klein-Szanto et al., 1992) .
